Markets:

Overview

News

Currencies

International

Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

329.57 +8.41 (+2.62%)

Delayed Quote Updated: 2:36 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Recap: Krystal Biotech Q3 Earnings ↗

November 07, 2022

Krystal Biotech (NASDAQ:KRYS) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

Recap: Krystal Biotech Q4 Earnings ↗

February 28, 2022

Krystal Biotech (NASDAQ:KRYS) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review ↗

August 18, 2022

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with...

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study ↗

August 01, 2022

The United States Food and Drug Administration (FDA) has accepted Krystal Biotech’ (NASDAQ: KRYS) Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis...

Via Benzinga

Krystal Biotech Files To Seek Approval For Skin Disease Candidate ↗

June 22, 2022

Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of...

Via Benzinga

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗

April 14, 2022

On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.

Via Investor's Business Daily

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise ↗

January 18, 2022

Krystal Biotech Inc (NASDAQ:KRYS) shares have po...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 ↗

January 18, 2022

Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:

Via Benzinga

Why Krystal Biotech's Shares Rose More Than 77% This Week ↗

December 02, 2021

The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease.

Via The Motley Fool

Why Krystal Biotech Stock Is Retreating Today ↗

December 01, 2021

A public offering is weighing on the biotech's shares today.

Via The Motley Fool

The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout ↗

November 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 29, 2021

Gainers Cumberland (NASDAQ:CPIX) share...

Via Benzinga

50 Biggest Movers From Yesterday ↗

November 30, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...

Via Benzinga

Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher ↗

November 29, 2021

Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also rose, gaining 1.55% to 4,665.67. The U.S. has...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 29, 2021

Gainers Krystal Biotech (NASDAQ:KRYS) shares moved upwards by 118.21% to $86.87 during Monday's regular session. Krystal Biotech's stock is trading at a volume of...

Via Benzinga

Stocks Rise as "Fear Gauge" Cools Off ↗

November 29, 2021

The Dow Jones Industrial Average and Nasdaq Composite are both up triple digits midday, paring some of their losses from Friday's massive selloff.

Via Talk Markets

Topics Stocks

Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide ↗

November 29, 2021

Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11. The U.S. has the...

Via Benzinga

Topics Stocks

33 Stocks Moving In Monday's Mid-Day Session ↗

November 29, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational...

Via Benzinga

KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% Today ↗

November 29, 2021

Krystal Biotech (KRYS) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial of VYJUVEK.

Via InvestorPlace

Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views ↗

November 29, 2021

Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also rose, gaining 0.92% to 4,637.03. The U.S....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 29, 2021

Gainers Krystal Biotech (NASDAQ:

Via Benzinga

Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To Know ↗

November 29, 2021

Krystal Biotech Inc (NASDAQ: KRYS) has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for...

Via Benzinga

61 Biggest Movers From Yesterday ↗

November 23, 2021

Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare...

Via Benzinga

40 Stocks Moving In Monday's Mid-Day Session ↗

November 22, 2021

Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

All News about Krystal Biotech, Inc. - Common Stock

Starting at /week.